Sage Journals: Discover world-class research

Abstract

Three nucleoside analogues, zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), are approved for use in the treatment of patients with HIV infection. This retrospective study compares the 3 drugs and examines the overall utility of antiretroviral therapy by way of comparisons to a no treatment (No Rx) group in patients with advanced HIV disease. Patients with advanced HIV disease were enrolled in didanosine (August 1989–December 1990) or zalcitabine (October 1990–February 1992) expanded access programmes; continued on zidovudine treatment despite fulfilling criteria for zidovudine failure or intolerance; or maintained on no antiretroviral treatment.

Statistical analysis revealed that patients on nucleoside analogue therapy had fewer opportunistic infections (P = 0.001) than those who received no antiretroviral treatment. The Kaplan-Meier 12-month estimate of survival was significantly longer among patients who switched from zidovudine to zalcitabine but not among patients who switched to didanosine, when compared to the other 2 groups (P = 0.05).

Keywords

HIV antiretroviral zidovudine didanosine zalcitabine

Get full access to this article

View all access options for this article.

References

Merigon

Skowron

Bozzette

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. Ann Intern Med 1989;110:189–94.

Yarchoan

Thomas

Allain

Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine. Lancet 1987;i:76–87.

Yarchoan

Mitsuya

Thomas

In vivo activity against HIV and favorable toxicity of 2,3′-dideoxyinosine. Science 1989;245:412–5.

Cooley

Kunches

Saunders

Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: A Phase I trial. N Engl J Med 1990;322:1333–40.

Lambert

Seidlin

Reichman

2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Lancet 1990;336:526–9.

Kahn

Lagakos

Richman

DD.

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus injection. N Engl J Med 1992;327:581–7.

Dolin

Amato

Fischi

Efficacy of didanosine (ddI) versus zidovudine (ZDV) in patients with no or ≤ 16 weeks of prior ZDV therapy (abstract WS-B24–1). Ninth International Conference on AIDS, 1993, Berlin.

Bristol Myers Squibb Co., 2400 W. Lloyd Expressway, R-22, Evansville, IN 47721–1001. VIDEX package insert.

Follansbee

Drew

Pollard

The efficacy of zalcitabine (ddC, HIVID) versus zidovudine (ZDV) as monotherapy in ZDV naïve patients with advanced HIV disease. A randomized double-blind comparative trial (ACTG 114: N3300) (abstract PO-B26–2113). Ninth International Conference on AIDS, 1993, Berlin.

10.

Fischi

Olson

Rollonsbee

Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 infection Who Received Previous Zidovudine Therapy. Ann Intern Med 1993;118:762–9.

11.

Roche Laboratories, 340 Kingsland Street, Nutley, New Jersey 07110–1199. HIVID package insert.

12.

Lipsky

JL.

Zalcitabine and didanosine. Lancet 1993;341:30–2.

13.

Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immune deficiency syndrome. MMWR 1987;36:15–15S.

14.

Fischi

Richman

Grieco

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind placebo-controlled trial. N Engl J Med 1987;317:185–91.

15.

Fischi

Richman

Causey

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1990:262:2405–10.

16.

Yarchoan

Pluda

Thomas

Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526–9.

17.

Larder

Kemp

SD.

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1990;246:1155–8.

18.

D'Aquila

Johnson

Kuritzkes

HIV-1 drug resistance and syncytium-inducing phenotype: Associations with disease progression among ACTG 116B/117 subjects (abstract PO-B26–2046). Ninth International Conference on AIDS, 1993, Berlin.

19.

Abrams

Goldman

Launer

A Comparative Trial of Didanosine or Zalcitabine in Patients with Human Immunodeficiency Virus Infection. N Engl J Med 1994;330:657–62.

20.

Darbyshire

Aboulker

JP.

Didanosine for zidovudine-intolerant patients with HIV disease. Lancet 1992;340:1346–7.

A Comparison of Zidovudine,Didanosine,Zalcitabine and No Antiretroviral Therapy in Patients with Advanced HIV Disease

Abstract

Keywords

Get full access to this article

References